Ninety One UK 13F: Cuts Johnson & Johnson (JNJ) Stake by $76M
Institutional filing reveals Ninety One UK trimmed its exposure to healthcare giant Johnson & Johnson.
Reviewed by automated data checks against the source filing. How we make and check alerts
Ninety One UK sold 285,326 shares from its stake in Johnson & Johnson ($JNJ), a 4.21% decrease, according to a 13F filing with the SEC dated October 15, 2026. It reported 6,491,294 shares worth $1.72 billion at the end of the quarter.
Since the filing, $JNJ is up 0.9% to date (from the $253.28 close on Oct 15, 2026).
JNJ
Johnson & Johnson
Key Points
- Ninety One UK cut its Johnson & Johnson position by 4.2% in an SEC filing disclosed on October 15, 2026.
- The fund held 6,491,294 shares valued at roughly $1.72 billion at the time of the report.
- Johnson & Johnson shares recently traded around $255.22 as major Wall Street firms update their price targets.
Get $JNJ trade alerts by text
We text you when insiders, Congress or big funds trade $JNJ. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures
Ninety One UK scaled back its investment in Johnson & Johnson (NYSE: JNJ), according to a Form 13F filing with the SEC on October 15, 2026. The institutional report covers holdings as of the end of the reporting period and may not show the fund's exact current share count today.
What Changed in Ninety One UK's Johnson & Johnson Position
During the period, Ninety One UK lowered its stake by 285,326 shares. That marked a 4.2% decrease from its previous holding of 6,776,620 shares. The remaining position stood at 6,491,294 shares with a reported value of $1,718,505,190.
Other Institutional Activity in Johnson & Johnson
Other large money managers also adjusted their positions in the healthcare firm around recent reporting periods. Blackrock Inc. reduced its holdings by 1,280,271 shares, ending with 212,098,264 shares worth about $54,203,831,830. Vanguard Capital Management LLC grew its holdings by 626,400 shares, ending with 157,226,374 shares worth about $40,180,771,755. State Street Corporation increased its stake by 293,661 shares to hold 133,776,025 shares valued at about $34,187,800,622. Vanguard Portfolio Management LLC boosted its stake by 857,431 shares, closing out the period with 64,370,816 shares worth about $16,450,605,579. Geode Capital Management, LLC trimmed its holdings by 76,912 shares, leaving it with 59,086,417 shares valued at about $15,100,124,584.
Johnson & Johnson Stock Up 0.5%
Johnson & Johnson shares recently traded around $255.22 as of October 16, 2026. The stock sits below its 50-day moving average of $265.26 and above its 200-day moving average of $243.87. Over the past year, shares have moved between a low of $184.66 and a high of $281.07.
Recent Earnings
Johnson & Johnson generated trailing-twelve-month revenue of $99.33 billion alongside earnings of $6.59 per share. The company reported a net profit margin of 16.2%. The next quarterly earnings report is scheduled for release on January 26, 2027.
Dividend
Johnson & Johnson pays an annual dividend yielding 2.12% with a payout ratio of 60.7%.
Insider Buying and Selling at Johnson & Johnson
Company insiders executed several stock transactions ahead of the filing. On August 6, 2026, officer Elizabeth Forminard sold 15,918 shares valued at $4,090,960. Chief Executive Officer Joaquin Boix Duato sold 123,291 shares on August 13, 2026, for a total of $32,199,927. Officer Jennifer L Taubert sold 15,000 shares on August 17, 2026, at an average price of $263.36, totaling $3,950,400. Later, on September 2, 2026, officer Timothy Schmid sold 33,597 shares at an average price of $274.74 worth $9,230,440.
Analysts Set New Price Targets
Analyst firms have updated their outlooks on the stock recently. On October 7, 2026, Guggenheim reiterated its buy rating with a $287.00 price target. Leerink Partners maintained an outperform rating on October 14, 2026, while adjusting its price target to $272.00 from $276.00. Wells Fargo maintained an overweight rating on October 14, 2026, moving its price target to $275.00 from $282.00. RBC Capital maintained an outperform rating on October 14, 2026, lowering its target to $280.00 from $290.00. Morgan Stanley maintained an overweight rating on October 15, 2026, with a target of $292.00. Overall, the stock holds a consensus buy rating with an average target price of $279.41 across 22 analyst opinions.
About Johnson & Johnson
Johnson & Johnson operates as a healthcare products company focused on medical technology and pharmaceutical innovations worldwide. It researches, develops, and manufactures treatments and devices through its Innovative Medicine and MedTech segments. Institutional adjustments by firms like Ninety One UK offer a window into how large managers reallocate capital across major pharmaceutical holdings.
Bottom Line
Investors tracking Ninety One UK will need to watch subsequent SEC filings to see if the fund continues trimming its stake. The company's next earnings report in late January will provide an updated look at financial performance. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.
Related Filing Alerts
Source: Ninety One UK's 13F filing on $JNJ (Oct 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Ninety One UK 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts